In pancreatic cancer, overexpression of Piezo1 is closely associated with tumor malignancy, drug resistance, and poor patient prognosis (Swain et al., 2022; Xie et al., 2025c). Here, PIEZO1 is linked to familial pancreatic carcinoma.